AAPL299.43+2.42 (+0.81%) ▲|ABBV234.34+4.33 (+1.88%) ▲|ABT90.27+2.44 (+2.77%) ▲|ACN126.48+1.65 (+1.32%) ▲|ADBE196.81+1.91 (+0.98%) ▲|AMAT582.66-57.52 (-8.99%) ▼|AMD521.69-29.94 (-5.43%) ▼|AMGN347.21+2.49 (+0.72%) ▲|AMT176.94+0.51 (+0.29%) ▲|AMZN234.09+1.30 (+0.56%) ▲|AVGO380.98-11.16 (-2.84%) ▼|AXP337.82-0.26 (-0.08%) ▼|BA218.75-2.08 (-0.94%) ▼|BAC57.84+0.47 (+0.82%) ▲|BKNG167.94+0.17 (+0.10%) ▲|BLK1,030.89-20.85 (-1.98%) ▼|BMY55.38+0.68 (+1.24%) ▲|BNY147.98+1.54 (+1.05%) ▲|BRK-B493.71+5.02 (+1.03%) ▲|C145.82+0.15 (+0.10%) ▲|CAT986.47-35.82 (-3.50%) ▼|CL90.92+2.25 (+2.54%) ▲|CMCSA22.78+0.46 (+2.04%) ▲|COF199.94-0.76 (-0.38%) ▼|COP110.10+0.40 (+0.36%) ▲|COST961.91+10.56 (+1.11%) ▲|CRM152.59+2.47 (+1.65%) ▲|CSCO119.59-1.94 (-1.60%) ▼|CVS101.82+0.52 (+0.51%) ▲|CVX175.65+0.59 (+0.34%) ▲|DE598.23-0.36 (-0.06%) ▼|DHR178.17-0.03 (-0.01%) ▼|DIS103.11+0.66 (+0.64%) ▲|DUK125.20+1.68 (+1.36%) ▲|EMR144.49-5.72 (-3.81%) ▼|FDX322.87-5.91 (-1.80%) ▼|GD348.01+4.65 (+1.35%) ▲|GE357.11+1.99 (+0.56%) ▲|GEV1,051.83-75.76 (-6.72%) ▼|GILD126.09+1.22 (+0.97%) ▲|GM79.48-0.96 (-1.19%) ▼|GOOG346.16-2.62 (-0.75%) ▼|GOOGL346.70-2.86 (-0.82%) ▼|GS1,099.85-6.52 (-0.59%) ▼|HD327.00+0.38 (+0.12%) ▲|HON224.81-3.31 (-1.45%) ▼|IBM265.24+13.02 (+5.16%) ▲|INTC135.87-5.07 (-3.60%) ▼|INTU260.03+2.26 (+0.87%) ▲|ISRG399.69-3.27 (-0.81%) ▼|JNJ235.47+4.18 (+1.81%) ▲|JPM334.79+3.31 (+1.00%) ▲|KO80.15+0.62 (+0.78%) ▲|LIN518.02+1.31 (+0.25%) ▲|LLY1,100.45-1.63 (-0.15%) ▼|LMT500.55+6.95 (+1.41%) ▲|LOW214.97+0.57 (+0.27%) ▲|LRCX368.16-41.39 (-10.11%) ▼|MA487.83+3.74 (+0.77%) ▲|MCD272.33+2.23 (+0.82%) ▲|MDLZ60.76+1.25 (+2.09%) ▲|MDT80.40+1.13 (+1.43%) ▲|META564.13+0.28 (+0.05%) ▲|MMM162.64-0.58 (-0.36%) ▼|MO71.09+1.58 (+2.27%) ▲|MRK118.26+2.78 (+2.41%) ▲|MS226.68-0.42 (-0.18%) ▼|MSFT374.62+7.28 (+1.98%) ▲|MU1,084.53-126.85 (-10.47%) ▼|NEE86.68+0.60 (+0.69%) ▲|NFLX72.69-0.19 (-0.26%) ▼|NKE42.42-0.77 (-1.78%) ▼|NOW96.71+3.70 (+3.98%) ▲|NVDA200.95-7.71 (-3.69%) ▼|ORCL170.02-5.06 (-2.89%) ▼|PEP141.65+0.94 (+0.67%) ▲|PFE24.87-0.21 (-0.84%) ▼|PG150.78+3.10 (+2.10%) ▲|PLTR118.58-0.92 (-0.77%) ▼|PM178.41+5.24 (+3.02%) ▲|QCOM199.77-22.13 (-9.97%) ▼|RTX183.96+2.13 (+1.17%) ▲|SBUX99.96-0.19 (-0.19%) ▼|SCHW92.83+0.80 (+0.87%) ▲|SO94.82+1.39 (+1.48%) ▲|SPG216.89+2.32 (+1.08%) ▲|T22.61+0.51 (+2.29%) ▲|TMO464.96+0.95 (+0.20%) ▲|TMUS182.64+2.58 (+1.43%) ▲|TSLA384.84-20.21 (-4.99%) ▼|TXN304.90-27.38 (-8.24%) ▼|UBER70.45-0.99 (-1.38%) ▼|UNH404.19-2.50 (-0.61%) ▼|UNP261.09+1.18 (+0.45%) ▲|UPS106.43-0.81 (-0.76%) ▼|USB59.60+0.92 (+1.57%) ▲|V330.90+4.30 (+1.32%) ▲|VZ46.09+0.73 (+1.60%) ▲|WFC84.02+0.18 (+0.21%) ▲|WMT119.63+2.45 (+2.09%) ▲|XOM139.47+1.00 (+0.72%) ▲|AAPL299.43+2.42 (+0.81%) ▲|ABBV234.34+4.33 (+1.88%) ▲|ABT90.27+2.44 (+2.77%) ▲|ACN126.48+1.65 (+1.32%) ▲|ADBE196.81+1.91 (+0.98%) ▲|AMAT582.66-57.52 (-8.99%) ▼|AMD521.69-29.94 (-5.43%) ▼|AMGN347.21+2.49 (+0.72%) ▲|AMT176.94+0.51 (+0.29%) ▲|AMZN234.09+1.30 (+0.56%) ▲|AVGO380.98-11.16 (-2.84%) ▼|AXP337.82-0.26 (-0.08%) ▼|BA218.75-2.08 (-0.94%) ▼|BAC57.84+0.47 (+0.82%) ▲|BKNG167.94+0.17 (+0.10%) ▲|BLK1,030.89-20.85 (-1.98%) ▼|BMY55.38+0.68 (+1.24%) ▲|BNY147.98+1.54 (+1.05%) ▲|BRK-B493.71+5.02 (+1.03%) ▲|C145.82+0.15 (+0.10%) ▲|CAT986.47-35.82 (-3.50%) ▼|CL90.92+2.25 (+2.54%) ▲|CMCSA22.78+0.46 (+2.04%) ▲|COF199.94-0.76 (-0.38%) ▼|COP110.10+0.40 (+0.36%) ▲|COST961.91+10.56 (+1.11%) ▲|CRM152.59+2.47 (+1.65%) ▲|CSCO119.59-1.94 (-1.60%) ▼|CVS101.82+0.52 (+0.51%) ▲|CVX175.65+0.59 (+0.34%) ▲|DE598.23-0.36 (-0.06%) ▼|DHR178.17-0.03 (-0.01%) ▼|DIS103.11+0.66 (+0.64%) ▲|DUK125.20+1.68 (+1.36%) ▲|EMR144.49-5.72 (-3.81%) ▼|FDX322.87-5.91 (-1.80%) ▼|GD348.01+4.65 (+1.35%) ▲|GE357.11+1.99 (+0.56%) ▲|GEV1,051.83-75.76 (-6.72%) ▼|GILD126.09+1.22 (+0.97%) ▲|GM79.48-0.96 (-1.19%) ▼|GOOG346.16-2.62 (-0.75%) ▼|GOOGL346.70-2.86 (-0.82%) ▼|GS1,099.85-6.52 (-0.59%) ▼|HD327.00+0.38 (+0.12%) ▲|HON224.81-3.31 (-1.45%) ▼|IBM265.24+13.02 (+5.16%) ▲|INTC135.87-5.07 (-3.60%) ▼|INTU260.03+2.26 (+0.87%) ▲|ISRG399.69-3.27 (-0.81%) ▼|JNJ235.47+4.18 (+1.81%) ▲|JPM334.79+3.31 (+1.00%) ▲|KO80.15+0.62 (+0.78%) ▲|LIN518.02+1.31 (+0.25%) ▲|LLY1,100.45-1.63 (-0.15%) ▼|LMT500.55+6.95 (+1.41%) ▲|LOW214.97+0.57 (+0.27%) ▲|LRCX368.16-41.39 (-10.11%) ▼|MA487.83+3.74 (+0.77%) ▲|MCD272.33+2.23 (+0.82%) ▲|MDLZ60.76+1.25 (+2.09%) ▲|MDT80.40+1.13 (+1.43%) ▲|META564.13+0.28 (+0.05%) ▲|MMM162.64-0.58 (-0.36%) ▼|MO71.09+1.58 (+2.27%) ▲|MRK118.26+2.78 (+2.41%) ▲|MS226.68-0.42 (-0.18%) ▼|MSFT374.62+7.28 (+1.98%) ▲|MU1,084.53-126.85 (-10.47%) ▼|NEE86.68+0.60 (+0.69%) ▲|NFLX72.69-0.19 (-0.26%) ▼|NKE42.42-0.77 (-1.78%) ▼|NOW96.71+3.70 (+3.98%) ▲|NVDA200.95-7.71 (-3.69%) ▼|ORCL170.02-5.06 (-2.89%) ▼|PEP141.65+0.94 (+0.67%) ▲|PFE24.87-0.21 (-0.84%) ▼|PG150.78+3.10 (+2.10%) ▲|PLTR118.58-0.92 (-0.77%) ▼|PM178.41+5.24 (+3.02%) ▲|QCOM199.77-22.13 (-9.97%) ▼|RTX183.96+2.13 (+1.17%) ▲|SBUX99.96-0.19 (-0.19%) ▼|SCHW92.83+0.80 (+0.87%) ▲|SO94.82+1.39 (+1.48%) ▲|SPG216.89+2.32 (+1.08%) ▲|T22.61+0.51 (+2.29%) ▲|TMO464.96+0.95 (+0.20%) ▲|TMUS182.64+2.58 (+1.43%) ▲|TSLA384.84-20.21 (-4.99%) ▼|TXN304.90-27.38 (-8.24%) ▼|UBER70.45-0.99 (-1.38%) ▼|UNH404.19-2.50 (-0.61%) ▼|UNP261.09+1.18 (+0.45%) ▲|UPS106.43-0.81 (-0.76%) ▼|USB59.60+0.92 (+1.57%) ▲|V330.90+4.30 (+1.32%) ▲|VZ46.09+0.73 (+1.60%) ▲|WFC84.02+0.18 (+0.21%) ▲|WMT119.63+2.45 (+2.09%) ▲|XOM139.47+1.00 (+0.72%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: drugs

newssourceFORcompanyinformationcontent1marketreleases

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

Doctor Discount Network Provides Essential Information for Safe Online Phentermine Purchases Amidst Growing Concerns

ELLENTON, Fla., June 20, 2025 /PRNewswire/ -- The convenience of online pharmacies has made them a popular source for prescription medications, including Phentermine, a...

PharmAla Files Preliminary Base Shelf Prospectus

Pharmala files short form prospectus

Health Net Providing Special Assistance to Members and Providers Affected by The Franklin Fire in Malibu Canyon in the City of Malibu, California

SACRAMENTO, Calif., June 20, 2025 /PRNewswire/ -- Following Gov. Newsom's declaration of a State of Emergency in Malibu Canyon in the City of Malibu,...

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at...

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrugs

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers